AI CuratorAI-generated

Research summary · 12 d ago

AI summary · not yet reviewedHuman studyObservationalTrial registry record – peer review not applicable

Participant Satisfaction with Ocrelizumab in Human MS Subjects

A study is planned to measure satisfaction levels of participants with relapsing or primary progressive multiple sclerosis after 12 months of receiving ocrelizumab subcutaneously. Participants will be evaluated with the Therapy Administration Satisfaction Questionnaire for Subcutaneous injections (TASQ-SC). No results from this study have been published yet.

Tags: #MSResearch
Most relevant to: —
Source: Read original source

This plain-English summary was written by AI from a trial registry record and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.

Human efficacy: Not yet assessed
Mechanism: Not yet assessed
Evidence strength: Not yet assessed
Outcome: Not yet assessed

Why it matters

Understanding participant satisfaction is important for assessing the acceptability of ocrelizumab as a treatment option for multiple sclerosis, influencing treatment adherence and patient outcomes.

What this does not prove

No results are available, and the absence of findings means conclusions cannot be drawn. Planned enrolment does not indicate actual outcomes.

Next milestone

No next milestone was established from the available source.

Study facts

Study design: Observational
Participants / samples: 842 · basis not reported
Randomised: No
Controlled: Not reported
Primary endpoint met: Not reported
Relevant MS type: Not reported
Publication date: Not reported
Evidence reviewed: Trial registry record
Regulatory approval: Not reported
Research areas: Not classified

Original sources

Trial registrationA Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS) ↗

Supporting passages (9)

study phaseTrial registry record. Publication date: unknown. No results are posted.

study design"officialTitle": "SurfSubQ - A Prospective Longitudinal Multicenter Observational Study to Investigate Neurofilament Light Chain Levels and Patient Satisfaction After Subcutaneous Ocrelizumab Administration in Persons With Multiple Sclerosis",

subjects"briefSummary": "The main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneously (SC) after 12 months using the therapy administration satisfaction questionnaire subcutaneous (TASQ-SC)."

sample size"studyPopulation": "Participants with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), diagnosed according to McDonald criteria of 2017 or revised McDonald criteria 2024, and treated with ocrelizumab SC for the first time during routine clinical practice will be observed in this study.",

randomizedNo results are posted.

intervention"description": "Participants who are receiving ocrelizumab, SC injection, for the first time as part of their routine MS therapy at physician's discretion in accordance with local clinical practice and/or labeling will be observed for treatment satisfaction with SC injection for up to 12 months.",

primary endpoint"measure": "Number of Participants by Their Level of Satisfaction With Ocrelizumab SC After the First Injection and After 6 Months Assessed Using TASQ-SC",

findings"briefSummary": "The main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneously (SC) after 12 months using the therapy administration satisfaction questionnaire subcutaneous (TASQ-SC)."

limitationsNo results are posted. Planned enrolment and endpoints are not findings.

AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.